Shop Antibodies
Anti-Mouse B Cell (Depletion) Antibody Production Strategy

Anti-Mouse B Cell (Depletion) Antibody Production Strategy

Anti-Mouse B cell antibody is recombinant mouse immunoglobulin (Ig) G2a-kappa monoclonal antibody engineered from Rituximab by fusing the Fv domain of Rituximab with mouse Fc domain.

Anti-Mouse B Cell (Depletion) Antibody

$475.00 – $6,950.00

Item Cat No.: BCDPAB

Antibody: Monoclonal Antibody

Concentration: 1 mg/ml

Application: B cell depletion

Reactivity: Mouse

BiCell Scientific Inc’s mouse B cell depletion antibody is a recombinant mouse immunoglobulin (Ig) G2a-kappa monoclonal antibody against CD20 protein.

Cluster of differentiation 20 (CD20, Ly-44, or B-lymphocyte antigen) is a ~35 kDa membrane protein expressed by resting and activated B lymphocytes, as well as most malignant B cells, which makes it an ideal target for antibody-based immunotherapies.

Rituximab, sold under the brand name Rituxan, is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen. Rituximab is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences.

BiCell Scientific Inc’s mouse B cell depletion antibody is a recombinant mouse immunoglobulin (Ig) G2a-kappa monoclonal antibody that fuses Rituximab’s light and heavy-chain variable region sequences with mouse constant region sequences. BiCell Scientific Inc’s mouse B cell depletion antibody is used at the dosage of 10 mg (antibody)/kg (body weight) via I.P. injection.

Host/Isotype: Mouse/IgG2a

Class: Monoclonal

Immunogen: Human CD20 protein

Production platform: CHO cells

Purification: Affinity chromatography

Storage buffer: PBS, pH 7.2

Storage condition: –20°C

For Research Use Only. Not for use in clinical diagnostics or therapeutics.

Additional information

Antibody Production Scale

1 mg, 10 mg, 100 mg

Reviews

There are no reviews yet.

Be the first to review “Anti-Mouse B Cell (Depletion) Antibody”

Related products

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

"The rabbit hybridoma supernatants of anti-APOBEC3 project are tested positive by ELISA, and we are very happy about it! We previously tried a company, Abclone. Their Project "A" has immune response that is <10,000 titer in antiserum, which would explain why there is no positive mAb after fusion. Their project "B" didn't have any immune response in rabbit."

Harshita B Gupta, PhD.

School of Medicine | UT Health San Antonio

"We have tested anti mouse T cell antiserum samples from both rabbits you sent to us.

They worked very well! Thank you!"

Victoria Gorbacheva, PhD.

School of Medicine | Cleveland Clinic

Contact us for questions or custom requests!

Email Us